International comparative field study of N8 evaluating factor VIII assay performance.
about
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AA new recombinant factor VIII: from genetics to clinical use.Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogsNovel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.Novel products for haemostasis - current status.Monitoring of modified factor VIII and IX products.Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia AA critical appraisal of one-stage and chromogenic assays of factor VIII activity.Updates from guardian™: a comprehensive registration programme.Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.Validation of an automated chromogenic assay of potency of factor VIII in commercial concentrates.Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays.Standards and monitoring treatment.BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
P2860
Q28075081-E753D346-9AFC-408C-B246-40A569DD547CQ30370282-4E8CF85F-8BBD-4EBC-B5DE-42F2EEA4B217Q33820925-96E2595C-A923-431F-BC6A-9E38DBF03962Q35778288-D992D6B0-D53E-4427-A7F5-BBFCE6B0CCFFQ37591484-3788C44A-8CA2-49DF-A5B1-E095506A5749Q38079624-3053DB91-FD6D-49BF-B159-643EF2E33B97Q38206849-2E8202C3-A609-45CA-B977-4D4BE0D011E0Q38206851-D453B4E9-5596-4207-9910-FD94D6038F1EQ38209486-31FBEE54-700D-4B71-AADF-D7B4EB628AE7Q38408739-2F4746F2-7920-47D2-9E7D-C58C232AC806Q38668506-4E530B43-2E60-4A61-B7FE-14E3947751DDQ38672491-0E9DEADA-BA29-48B5-9FCB-40EB4B7F7412Q38796270-C7527612-3421-4211-A474-F1400FA54FF4Q38894174-20B933E8-3852-4F3D-A987-A346267E58CAQ39648285-F29E227C-D00C-49CE-A303-81971AB18D92Q39898980-49D68ADB-3FB0-4BE1-AE1E-ABEBFA53115BQ42971075-A770CACB-FA3E-4081-8E36-36569EC87A5CQ45004372-2CF0BF33-79EF-42AB-8A6A-8421C935E65FQ45384410-15DCE1B2-9F5C-4183-8325-18A4AF6685BBQ45864807-3E37E089-5037-416E-B698-6920ECF940CCQ45872443-7CD06FA7-BB1F-4F1C-A3B1-70F82DE45719Q45873106-E402D07D-202E-4E48-8531-AE89D4ACD327Q45875490-2526AAA7-B218-4406-A674-5DF73B7479EDQ45879932-7720FA90-548F-4EEC-88D0-B8DF096FDDE5Q45884519-4396348B-078A-46C6-9D17-FEDC49F9C436Q45887360-8A37EBDB-0EDA-481D-AFCB-64769FE89E5AQ45887366-A6CEDEED-76CA-4CE1-8928-B6A0DCC0ABB4Q45887401-D7A8C146-E424-4821-9144-9F5937E277ECQ45887550-4ADC3FD0-BD13-4926-9A40-EB77B01763A7
P2860
International comparative field study of N8 evaluating factor VIII assay performance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
International comparative field study of N8 evaluating factor VIII assay performance.
@en
International comparative field study of N8 evaluating factor VIII assay performance.
@nl
type
label
International comparative field study of N8 evaluating factor VIII assay performance.
@en
International comparative field study of N8 evaluating factor VIII assay performance.
@nl
prefLabel
International comparative field study of N8 evaluating factor VIII assay performance.
@en
International comparative field study of N8 evaluating factor VIII assay performance.
@nl
P2093
P2860
P1433
P1476
International comparative field study of N8 evaluating factor VIII assay performance.
@en
P2093
D Lillicrap
T Saugstrup
Tw Barrowcliffe
P2860
P304
P356
10.1111/J.1365-2516.2010.02481.X
P577
2011-03-22T00:00:00Z